Metamark Genetics, established in 2007, positions itself as a frontrunner in the field of comprehensive urology cancer care. With its slogan "Metamark - A leader in comprehensive urology cancer care," the company is anchored in breakthrough diagnostic and prognostic testing aimed at enhancing cancer treatment outcomes.
Headquartered in the United States, Metamark operates within the Biotechnology, Health Care, and Health and Wellness industries. Since inception, the firm has made significant strides in clinical proteomics, focusing particularly on prostate and bladder cancer, leveraging its deep expertise in molecular diagnostics.
The company last secured a $13.00M Series B investment on 05 November 2012, which supports its ongoing innovation and expansion endeavors.